Lilly Asia Ventures

Lilly Asia Ventures, which originated from the venture capital department of Eli Lilly and Company in 2008, became an independent investment management company in 2011 and has since grown into a leading life sciences and healthcare venture capital fund in the industry. As one of the earliest professional biopharmaceutical funds to begin operations in China, we have been continuously investing in China's healthcare industry for a decade and have gradually expanded our investments to the United States. Our team, guided by the principles of integrity, innovation, and collaboration, consists of over 30 accomplished professionals in scientific research, clinical medicine, investment management, and operations. Currently, we manage six U.S. dollar funds and five RMB funds with a total value exceeding 4.5 billion U.S. dollars. Lilly Asia Ventures is headquartered in China, with offices in Shanghai, Hong Kong, and Silicon Valley in the United States.